Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2-IN-1), Purified Small Molecule

As low as US$137.00
Please choose unit size

Catalog Number
PE-1608

    Product Info

  • Product Name Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2-IN-1), Purified Small Molecule
  • Product Description google Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2-IN-1), Purified Small Molecule, suitable to Block.
  • Alternative Names Protein: Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin; LRRK2; PARK8
  • Application(s) Block
  • Purity Description >97% by HPLC
  • Purity % > 97%
  • Regulatory Status For research use only.

    Specifications

  • Product Description Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2-IN-1), Purified Small Molecule, suitable to Block.
  • Application(s) Block
  • Application Details Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
  • Target Leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2-IN-1)
  • Target Host Species Human
  • Purity Description >97% by HPLC
  • Purity % > 97%
  • Format Dry, Synthetic chemical powder
  • Storage Instructions Store dry, unopened vial protected from light for up to 3 months at RT or at -70ºC for up to 1 year. Reconstitute product in 100% ACS grade DMSO and store at -80ºC, in aliquots, protected from light, for up to 1 month. Prevent multiple freeze-thaw cycles. CAS Number 1234480-84-2.
  • Batch Number Please see item label.
  • Expiration Date 12 months after date of receipt (unopened vial).
  • Alternative Names Protein: Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin; LRRK2; PARK8
  • Scientific Background Leucine-Rich Repeat Kinase 2 (LRRK2) is a member of the leucine-rich repeat kinase family. Mutations in the LRRK2 gene have been linked with late-onset autosomal dominant Parkinson's disease (PD). A recent screening identified the analog LRRK2-IN-1 as a potent and selective inhibitor of LRRK2. This research by Deng et al (2011, Nat Chem Biol) showed that LRRK2-IN-1 suppressed LRRK2 kinase activity in vivo leading to dephosphorylation of Ser910/Ser935, loss of 14-3-3 binding and accumulation of LRRK2 within aggregrate fibrillar structures. LRRK2-IN-1, is the first selective and potent inhibitor of LRRK2. LRRK2-IN-1 inhibits both wild-type and G2019S mutant LRRK2 kinase activity with IC50 values of 13nM and 6nM respectively (Deng et al 2011, Nat Chem Biol).
  • Shipping Temperature 25°C (ambient)
  • UNSPSC CODE 12352401
  • Regulatory Status For research use only.

    Images, Protocols & SDS

    Citations & References

  • Specific References Deng X. et al (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat Chem Biol. 2011 Apr;7(4):203-5.